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BACKGROUND: Angiogenic processes in the placenta are critical births, 25.6% for small-for-gestational-age births, and 2.8% for stillbirth.
regulators of fetal growth and impact birth outcomes, but there are limited
data documenting these processes in HIV-infected women or women from
low-resource settings.
OBJECTIVE: We sought to determine whether angiogenic factors are
associated with adverse birth outcomes in HIV-infected pregnant women
started on antiretroviral therapy.
STUDY DESIGN: This is a secondary analysis of samples collected as
part of a clinical trial randomizing pregnant women and adolescents infected
with HIV to lopinavir/ritonavir-based (n¼ 166) or efavirenz-based (n¼ 160)
antiretroviral therapy in Tororo, Uganda. Pregnant women living with HIV
were enrolled between 12-28 weeks of gestation. Plasma samples were
evaluated for angiogenic biomarkers (angiopoietin-1, angiopoietin-2,
vascular endothelial growth factor, soluble fms-like tyrosine kinase-1,
placental growth factor, and soluble endoglin) by enzyme-linked immuno-
sorbent assay between: 16-<20, 20-<24, 24-<28, 28-<32, 32-<36,
36-<37 weeks of gestation. The primary outcome was preterm birth.
RESULTS: In all, 1115 plasma samples from 326 pregnant women and
adolescents were evaluated. There were no differences in angiogenic
factors according to antiretroviral therapy group (P > .05 for all). The
incidence of adverse birth outcomes was 16.9% for spontaneous pretermCite this article as: Conroy AL, McDonald CR, Gamble
JL, et al. Altered angiogenesis as a common mechanism
underlying preterm birth, small for gestational age, and
stillbirth in women living with HIV. Am J Obstet Gynecol
2017;217:684.e1-14.
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https://doi.org/10.1016/j.ajog.2017.10.003
684.e1 American Journal of Obstetrics& Gynecology DECEMBER 2017We used linear mixed effect modelling to evaluate longitudinal changes in
angiogenic factor concentrations between birth outcome groups adjusting
for gestational age at venipuncture, maternal age, body mass index,
gravidity, and the interaction between treatment arm and gestational age.
Two angiogenic factorsesoluble endoglin and placental growth factore
were associated with adverse birth outcomes. Significantly higher con-
centrations of soluble endoglin throughout gestation were found in study
participants destined to deliver preterm [likelihood ratio test, c2(1) ¼
12.28, P < .0005] and in those destined to have stillbirths [c2(1)¼ 5.67,
P< .02]. By contrast, significantly lower concentrations of placental growth
factor throughout gestation were found in those destined to have small-for-
gestational-age births [c2(1) ¼ 7.89, P < .005] and in those destined to
have stillbirths [c2(1) ¼ 21.59, P < .0001].
CONCLUSION: An antiangiogenic state in the second or third trimester
is associated with adverse birth outcomes, including stillbirth in women
and adolescents living with HIV and receiving antiretroviral therapy.
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tyrosine kinase-1, stillbirthIntroduction
It is estimated that 17.8 million of 36.7
million people living with HIV in 2015
were women and girls of reproductive age
(>15 years).1 Widespread use of com-
bined antiretroviral treatment (ART) has
dramatically reduced rates of vertical
transmission while improving maternal
health andbirthoutcomes.However, rates
of adverse birth outcomeseincludingpreterm birth (PTB), small for gestational
age (SGA), and stillbirtheremain higher
among women and adolescents living
with HIV (WLHIV) receiving ART than
HIV-uninfectedwomen.2-11There are few
studies investigating the mechanisms
associated with adverse birth outcomes in
pregnant WLHIV. As the number of
pregnant WLHIV having children in-
creases,12 it is important to understand
the disease processes underlying adverse
birth outcomes that, in turn,may facilitate
improved clinical management. Recently,
HIV was identiﬁed as a risk factor for
maternal vascular malperfusion in a
population of South African women.13
Robust placental function is essential
for fetal growth and development. Vas-
culogenic processes in the ﬁrst trimester
regulate de novo formation and growth
of blood vessels. Angiogenic processesbeginning in the second trimester induce
remodeling of the underlying placental
architecture to allow for increased blood
ﬂow and surface area for nutrient
exchange.14,15 Altered expression of
angiogenic factors is associated with
a number of complications in
pregnancy including preeclampsia,16-27
systemic lupus erythematosus and/or
antiphospholipid antibodies,28 fetal
growth restriction,22,29,30 preterm
delivery,31 and spontaneous abortion/
stillbirth,21,32,33 suggesting placental
stress responses triggered by placental
malperfusion can lead to systemic
changes in angiogenic factors.34-36
The vascular endothelial growth factor
(VEGF) family of proteins, including
placental growth factor (PlGF), are
proangiogenic mediators that are synthe-
sized by trophoblast, and endothelial cells
of the placental villi. VEGF and PlGF bind
VEGF receptor 1 (fms-like tyrosine kinase
ajog.org OBSTETRICS Original Research[Flt]-1) and VEGF binds VEGF receptor 2
on the endothelium to induce vascular
proliferation, migration, and sprout-
ing.14,37,38 Flt-1 can be alternatively
spliced to generate the antiangiogenic
protein soluble Flt (sFlt)-1.39 The angio-
poietins (Ang) bind their cognate
receptor, tyrosine-protein kinase Tie-2.
Ang-1 induces maturation and stabiliza-
tion of the vasculature while Ang-2
generally causes destabilization and in-
duces angiogenesis.15 Soluble endoglin
(sEng) is a soluble receptor of trans-
forming growth factor (TGF)-b that binds
TGF-b and reduces its bioavailability.40
sEng appears to inhibit the immunoreg-
ulatory actions of TGF-b and acts as
an antiangiogenic factor in the placenta
by inhibiting vascular permeability and
nitric-oxide-mediated vasodilation.40,41
Angiogenic processes in the placenta
affect pregnancy, but there are limited
data documenting these processes in the
context of HIV infection and low-
resource settings where rates of adverse
birth outcomes are the highest. We hy-
pothesize that alterations in angiogenic
factors are associated with adverse
birth outcomes in pregnant WLHIV. To
test this hypothesis we longitudinally
characterized circulating plasma levels of
angiogenic proteins in a cohort of
WLHIV initiated on ART.42 In this
report we describe the kinetics of
angiogenic factors over pregnancy,
compare angiogenic factors
between different ART regimens (efa-
virenz- vs lopinavir/ritonavir-based
ART), and evaluate whether angiogenic
factors predict adverse birth outcomes
(spontaneous PTB, SGA, and stillbirth).
Materials and Methods
Ethics statement
Written informed consent was obtained
from all participants. Ethical approval was
received fromMakerereUniversity School
of Medicine (Sept. 20, 2009; reference
2009-141); the Uganda National Council
for Science and Technology; the Univer-
sity of CaliforniaeSan Francisco (Aug. 9,
2009; reference 10-02958); and the Uni-
versity Health Network (March 13, 2014;
reference 14-7313-AE). This trial was
registered: ClinicalTrials.gov (identiﬁer:
NCT00993031).Study population
Plasma samples were collected from
pregnant WLHIV participating in a
randomized controlled trial of protease
inhibitor vs nonnucleoside reverse
transcriptase inhibitorebased ART in
Tororo, Uganda, from 2009 through
2013.42 Participants were HIV-infected,
16 years of age, and pregnant (12-28
weeks of gestation by last menstrual
period with conﬁrmation by ultra-
sound). Eligibility for enrollment was
not dependent on CD4 cell count.
Patients were ineligible to participate
if they had received ART (including
any abbreviated monotherapy) or dual
therapy with nevirapine in the last
24 months. Subjects received standard
antenatal care according to Ugandan
Ministry of Health Guidelines (http://
www.health.go.ug/docs/ucg_2010.pdf).
Blood pressure and urine protein was
assessed at enrollment and routine
antenatal visits. Participants on protease
inhibitorebased ARTreceived lopinavir/
ritonavir (n ¼ 166) and those on
nonnucleoside reverse transcriptase
inhibitorebased ART received efavirenz
(n ¼ 160). Socioeconomic status was
assessed as described.43
Laboratory assays
Blood collection and laboratory work
was performed at baseline and at all
subsequent antenatal visits. Clinical
tests included complete blood cell
count and determination of CD4þ/
CD8þ T-lymphocyte subsets. Standard-
ized assessments were completed at de-
livery including gestational age and
birthweight (using an electronic scale).
Study outcomes
Womenwere eligible for inclusion in this
secondary analysis if they had a singleton
pregnancy with known birth outcome,
and samples collected within 6 pre-
speciﬁed gestational age bins: 16-<20,
20-<24, 24-<28, 28-<32, 32-<36,
36-<37 weeks of gestation. The primary
exposure was biomarker levels and the
primary outcome was PTB (so samples
were not tested >36 weeks of completed
gestation). PTB was deﬁned as delivery
<37 weeks of gestation (ultrasound
dated), SGA was deﬁned usingDECEMBER 2017 AmeriINTERGROWTH standards,44 and still-
birth deﬁned as intrauterine fetal demise
20 weeks of gestation.
Enzyme-linked immunosorbent
assays
EDTA plasma samples were collected
and stored at 80C prior to testing.
Samples were tested in Uganda using
commercially available enzyme-linked
immunosorbent assays (Duosets, R&D
Systems, Minneapolis, MN) with the
following ranges, dilution factors, and
intraassay coefﬁcients of variation: Ang-
1 (313-20,000 pg/mL, 1:10, 5.6%); Ang-
2 (93.8-6000 pg/mL, 1:20, 6.1%); sEng
(250-16,000 pg/mL, 1:20, 7.4%); sFlt-1
(250-16,000 pg/mL, 1:5, 11.9%); PlGF
(63.0-4000 pg/mL, 1:5, 8.1%), and
VEGF (31-2000 pg/mL, 1:2). All testing
was performed blinded to group and
outcome.
Statistical analysis
Statistical analysis was performed using
STATA v14 (StataCorp, College Station,
TX), R v3.2.145 (R Foundation for Sta-
tistical Computing), and GraphPad
Prism v6 (GraphPad Software Inc, La
Jolla, CA) software. Descriptive statistics
were calculated as n (%) and median
(interquartile range). The c2 and Fisher
exact tests were used to compare cate-
gorical variables. Linear regression was
used to assess whether biomarker levels
changed over pregnancy. To assess the
effect of gestational age on angiogenic
factor concentrations between birth
outcome groups, we used the lme446
package in R45 to construct linear
mixed effects (LME) models with
random intercept and random slope,
adapting the approach employed by
Romero et al.32 For each biomarker and
outcome, we constructed a null model
with 4 ﬁxed effects: the linear effect of
gestational age, maternal age, body mass
index (BMI), and gravidity. To make the
intercept meaningful, the gestational age
variable was shifted such that the lowest
gestational age in our data set (the
baseline samples) would be the in-
tercept’s x-value. We also included the
interaction between gestational age and
treatment arm, to control for the possi-
bility that the treatment affected thecan Journal of Obstetrics& Gynecology 684.e2
FIGURE 1
Flow chart of maternal plasma samples processed by gestational age
ART, antiretroviral therapy; EFV, efavirenz; LPV/r, lopinavir/ritonavir.
Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017.
TABLE 1
Descriptive characteristics of study population
Cohort, n ¼ 326
Demographics
Age, y 30 (26e33)
BMI, kg/m2 21.4 (19.9e23.0)
Socioeconomic status, tertile
1 111 (35.9)
2 135 (43.7)
3 63 (20.4)
Gestational age at enrollment, wk 23.6 (19.6e27.9)
Previous pregnancies
0 20 (6.1)
1 35 (10.7)
2 271 (83.1)
Laboratory characteristics
Hemoglobin level, g/dL 11.0 (10.2e11.8)
White blood cell count, cells/mm3 5050 (4200e6200)
Platelet count, 109/L 210 (173e252)
CD4þ T-cell count, cells/mm3 369 (271e504)
HIV RNA load, log10 copies/mL 4.2 (3.9e4.8)
Delivery characteristics
Gestational age delivery, wk 38 (37e40)
Birthweight, kg 2890 (2670e3230)
Preterm birth 55 (16.9)
Small for gestational age 81 (25.6)
Stillbirth 9 (2.8)
Placental malariaa 24 (8.7)
Continuous variables expressed as median (interquartile range), categorical variables expressed as n (%).
BMI, body mass index.
a Defined by positive finding of placental blood smear or polymerase chain reaction.
Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017.
Original Research OBSTETRICS ajog.orgbiomarker’s rate of change. Treatment
arm was omitted as a main effect to
constrain the groups to have the same
intercept, as baseline differences between
the (randomly allocated) groups would
have been due to chance. In 2 additional
models, we added the birth outcome as a
ﬁxed effect: an additive, no-interaction
model and an interaction model. Both
models were the same as the null but
also included outcome as a main effect;
and the interaction model further
included the interaction between
outcome and gestational age. For none
of the biomarkers or birth outcomes did
the interaction term signiﬁcantly
improve the model ﬁt (P > .05 for all).
Therefore, the data favor the more
parsimonious additive models. For
models in which the groups had
different intercepts, the ﬁtted lines did
not signiﬁcantly converge or diverge
over time. For random effects, all
models included a by-participant inter-
cept and by-participant slope for the
effect of gestational age. The biomarker
levels were transformed using the natu-
ral logarithm to stabilize their variance.
Residual plots did not show any
apparent deviation from homoscedas-
ticity or normality. Statistical signiﬁ-
cance was assessed using likelihood ratio
(LR) tests, which compared in a stepwise
fashion the null model, the additive
model, and the interaction model. As
the PlGF values vary quadratically over
time, we added a quadratic interaction
term to the model, which signiﬁcantly
improved the model ﬁt [LR test, c2(1)¼
157.15, P < .0001].684.e3 American Journal of Obstetrics& Gynecology DECEMBER 2017
FIGURE 2
Angiogenic factors in HIV infected study participants receiving antiretroviral therapy
Scatter plot of plasma levels of angiogenic factors plotted according to gestational age of sample collection: A, placental growth factor (PlGF); B, soluble
fms-like tyrosine kinase (sFlt)-1; C, soluble endoglin (sEng); D, angiopoietin (Ang)-2; and E, Ang-1. Line indicates best fit line with 95% confidence
intervals.
Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017.
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Description of the study population
A total of 1115 plasma samples were
evaluated from 326 women and adoles-
cents (Figure 1). The demographic
characteristics of the study population
are presented in Table 1. The median age
of women was 30 years with a median
BMI at enrollment of 21.4 kg/m2. The
majority of participants (n ¼ 271, 83%)
were multigravida. None of the partici-
pants were diagnosed with chronic hy-
pertension, preeclampsia, or eclampsia
during the study period. Adverse birth
outcomes in the cohort were common
with 18.1% (n ¼ 59) of participants
having a low-birthweight infant
(compared to a national estimate of12%47), 16.9% (n ¼ 55) spontaneous
PTB, 25.6% (n ¼ 81) SGA, and 2.8%
(n¼ 9) stillborn. Themedian gestational
age of stillbirth deliveries was 31 weeks of
gestation. Cause of fetal demise was not
ascertained. Malaria infection status and
birth outcomes did not differ between
participants receiving lopinavir/ritona-
vir compared to those receiving efavirenz
(Supplemental Table 1).
Longitudinal changes in angiogenic
factors over pregnancy
There were no differences in angiogenic
proteins by trial arm (Supplemental
Figure 1), so subsequent analysis was
conducted using the combined cohort.
We plotted the longitudinal kinetics ofDECEMBER 2017 Ameriangiogenic factors over pregnancy and
observed declining levels of Ang-2 across
gestation, and increasing levels PlGF,
sFlt-1, and sEng (P < .0001 for all)
(Figure 2). There were no differences in
circulating Ang-1 levels across gestation.
Median plasma Ang-2 decreased from
6.6 ng/mL at 16-20 weeks to 2.5 ng/mL
by 37 weeks of gestation. Median levels
of sEng increased from 9.1-14.7 ng/mL
and sFlt-1 increased from 1.9-6.4 ng/mL
from 16-20 and 37 weeks of gestation
(Figure 2). PlGF levels were 0.24 ng/mL
at 16-20 weeks, peaked at 0.84 ng/mL at
28-32 weeks, and declined to 0.40 ng/mL
by 37 weeks of gestation (Figure 2).
VEGF-A levels were largely
undetectable with 87% of samplescan Journal of Obstetrics& Gynecology 684.e4
TABLE 2
Linear mixed effect modelling of longitudinal changes in soluble endoglin
and adverse birth outcomes
Preterm birth Stillbirth
Beta SE Beta SE
Fixed terms
(Intercept) 2.13733 0.1760 2.12762 0.1788
Birth outcome 0.16745 0.0475 0.26459 0.1110
Gestational age
(shifted)
0.04093 0.0030 0.04064 0.0030
Maternal age e0.00102 0.0047 e0.00154 0.0048
Enrollment BMI e0.00455 0.0063 e0.00297 0.0064
Gravidity e0.01270 0.0109 e0.01047 0.0111
Gestational age:
treatment arm
interaction
e0.00507 0.0025 e0.00471 0.0026
No. of subjects 320 320
Observations 1085 1085
LR test against
null model
c2(1) ¼ 12.282, P < .0005 c2(1) ¼ 5.6717, P < .02
Linear mixed effect modelling evaluated longitudinal changes in angiogenic factor concentrations between birth outcome
groups. Models adjusted for gestational age at venipuncture, maternal age, BMI, gravidity, and interaction between treatment
arm and gestational age.
BMI, body mass index; LR, likelihood ratio.
Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017.
Original Research OBSTETRICS ajog.orghaving concentrations below the bottom
standard of 31.3 pg/mL.
Relationship between angiogenic
factors and immune status
To determine whether angiogenic factors
were associated with maternal health or
immune status, we conducted nonpara-
metric bivariate correlations comparing
angiogenic proteins and enrollment
laboratory tests. There were no differ-
ences between angiogenic proteins
measured in the ﬁrst gestational age bin
(16-<20 weeks of gestation) and
enrollment hemoglobin, platelet count,
viral load, or CD4 count (P> .05 for all).
Relationship between angiogenic
factors and birth outcomes
LMEmodeling evaluated the longitudinal
changes in angiogenic factor concentra-
tions between birth outcome groups.
The models adjusted for gestational age
at venipuncture, maternal age, BMI,
gravidity, and the interaction between
treatment arm and gestational age
(Tables 2 and 3, and Supplemental
Tables 2-4). Two angiogenic factorse
sEng and PlGFewere associated with
adverse birth outcomes. Signiﬁcantly
higher concentrations of sEng throughout
gestationwere found in study participants
destined to deliver preterm [LR test,
c2(1) ¼ 12.28, P < .0005] (Figure 3, A)
and in those destined to have stillbirths
[c2(1) ¼ 5.67, P < .02] (Figure 3, B, and
Table 2). By contrast, signiﬁcantly lower
concentrations of PlGF throughout
gestation were found in those destined to
have SGA births [c2(1) ¼ 7.89, P < .005]
(Figure 3, C) and in those destined to have
stillbirths [c2(1) ¼ 21.59, P < .0001]
(Figure 3, D, and Table 3). To show the
natural variability of biomarkers over
gestation among individual participants,
we generated trellis plots for a random
subset of participants with the ﬁtted
regression line from the LME model
conditional on ﬁxed effects only
(Supplemental Figures 2-5).
Comment
Principal findings of the study
Angiogenic processes in the placenta are
critical regulators of fetal growth, but
there are limited data documenting these684.e5 American Journal of Obstetrics& Gynecolprocesses in low-resource settings where
maternal infections are common. In this
study we assessed longitudinal concen-
trations in angiogenic proteins in HIV-
infected pregnant women and adoles-
cents started on ART. There were no
differences in angiogenic factors by
treatment arm. All proteins except Ang-1
and VEGF-Awere dynamically regulated
over gestation. Ang-2 levels declined,
while sFlt-1 and sEng increased over
gestation, and PlGF increased up to 32
weeks of gestation and then declined.
Altered expression of angiogenic factors
was associated with spontaneous PTB,
SGA, and stillbirth. These data suggest an
early shift toward an antiangiogenic state
is a common pathway associated with
adverse birth outcomes in WLHIV,
consistent with data fromHIV-uninfected
women.22,31,32,34,48-50 Placental malaria
was uncommon in this study due to
the distribution of insecticide-treated
bed nets and daily prophylaxis with
trimethoprim-sulfamethoxazole.ogy DECEMBER 2017Comparison with previous studies
We evaluated 1115 plasma samples
collected from 326 women and adoles-
cents between 16-<37 weeks of gesta-
tion. We compared our ﬁndings directly
to results from women enrolled in a
clinical trial receiving calcium supple-
mentation in pregnancy with longitudi-
nal assessment of sFlt-1, PlGF and
VEGF,16 and sEng19 between 8-42 weeks
of gestation.51 Both sFlt-1 and sEng
levels increased over pregnancy starting
at 24-28 weeks of gestation. While levels
of sFlt-1 increased 3-fold over the third
trimester, levels of sEng reached a
plateau by 32-26 weeks of gestation.
PlGF levels increased in early pregnancy,
peaked between 28-32 weeks of gesta-
tion, and declined. Our results were
consistent with those from the calcium
trial suggesting temporal regulation of
angiogenic factors is tightly controlled
across pregnancy. In both studies, VEGF
was measured but was undetectable in
the majority of samples.
TABLE 3
Linear mixed effect modelling longitudinal changes in placental growth
factor and adverse birth outcomes
Small for gestational age Stillbirth
Beta SE Beta SE
Fixed terms
(Intercept) e3.03817 0.6134 e3.14340 0.5889
Birth outcome e0.38094 0.1357 e1.66380 0.3520
Gestational age (shifted) 0.36286 0.0264 0.36828 0.0259
Gestational age (shifted)
squared
e0.01379 0.0010 e0.01405 0.0010
Maternal age 0.01062 0.0163 0.00881 0.0156
Enrollment BMI e0.00981 0.0218 e0.00876 0.0208
Gravidity 0.06139 0.0379 0.07530 0.0359
Gestational age:
treatment arm
interaction
e0.00384 0.0087 e0.00421 0.0085
No. of subjects 311 320
Observations 1080 1104
LR test against
null model
c2(1) ¼ 7.892, P < .005 c2(1) ¼ 21.595, P < .0001
Linear mixed effect modelling evaluated longitudinal changes in angiogenic factor concentrations between birth outcome
groups. Models adjusted for gestational age at venipuncture, maternal age, BMI, gravidity, and interaction between treatment
arm and gestational age.
BMI, body mass index; LR, likelihood ratio.
Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017.
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role in placental vascular development,
data on Ang kinetics in pregnancy are
limited. Our observations are consistent
with a report of decreased placental
Ang-2 messenger RNA over preg-
nancy.14 Placental expression of Ang-2
messenger RNA is strongly correlated
with circulating Ang-2 protein levels.14
Our results are further supported by a
study examining plasma Ang levels be-
tween 10-37 weeks of gestation where
Ang-2 levels decreased and Ang-1
remained the same across gestation.52
Collectively these data demonstrate the
Ang-Tie-2 axis is dynamically regulated
over pregnancy.
There are limited data on the impact
of maternal HIV infection on expression
of angiogenic factors. Lower PlGF levels
have been reported in pregnant WLHIV
in South Africa53; however, the sample
size was small (n ¼ 27 HIV-uninfected,
n ¼ 31 WLHIV), and samples were
collected a week later in WLHIV. Otherstudies examining angiogenic factors in
nonpregnant individuals infected with
HIV have shown increases in the Ang-
2:Ang-1 ratio associated with acute
HIV infection, and decreased Ang-1 in
chronic disease.54 In HIV-infected
Kenyan women with advanced infec-
tion, Ang-2 levels decreased and Ang-1
levels increased following the initiation
of ART.55 On a cellular level, HIV-
infected cells release transactivator of
transcription, which accumulates on
and is taken up by endothelial cells
where it acts in synergy with VEGF-A to
modify the cytoskeletal structure of
endothelium.56,57
There have been a number of studies
investigating the relationship between
placental angiogenesis, vascular remod-
eling, and stillbirth. In a study of 22
unexplained stillbirths and 44 age-
matched live-born controls, stillbirth
was associated with increased placental
microvascular density, vasculopathy,
and increased vascular permeability,58DECEMBER 2017 Amerisuggesting increased vascular remodel-
ing in terminal stillbirth placentae. In
contrast, in 1269 singleton women with
samples collected between 30-34 weeks
of gestation, a low PlGF/sFlt-1 ratio was
associated with stillbirth.21 Levels of sFlt-
1 and sEng in the highest quartile of
amniotic ﬂuid were associated with
increased odds of stillbirth in women
with unexplained fetal death.23 In a
longitudinal nested case-control study of
women with a fetal death compared to
those with an appropriate-for-
gestational-age term delivery, the ﬁrst
trimester (weeks 7-11) was characterized
by a proangiogenic phenotype (low sFlt-
1, low sEng, high PlGF) and this shifted
in favor of an antiangiogenic phenotype
over the second and third trimester
(between 23-41 weeks of gestation).32
Another cohort showed low sFlt-1 and
PlGF levels in the ﬁrst trimester were
associated with spontaneous abortion.33
Our data support and extend the hy-
pothesis that an antiangiogenic state in
the second and third trimester is asso-
ciated with subsequent stillbirth with
lower PlGF and higher sEng levels. As
the placental vascular network un-
dergoes continual growth and remodel-
ing, it requires the coordinated
regulation of angiogenic factors in a
spatial, temporal, and quantitative
manner. Additional studies are needed to
assess how temporal changes in angio-
genic factors during pregnancy relate to
the vascular phenotype observed in the
placenta at delivery.
Beginning in the second trimester
the placenta undergoes a continuous
process of sprouting angiogenesis,
intercalated growth, and intussuscep-
tion. This remodeling allows for
increased placental volume and surface
area for nutrient exchange to support the
rapidly growing fetus. Dysregulation of
the pathways that mediate these pro-
cesses midpregnancy may result in pre-
term delivery or fetal growth restriction
if the placenta cannot support this rapid
growth. Relative increases in sEng levels
across gestation were associated with
spontaneous PTB in this cohort,
supporting the hypothesis that an anti-
angiogenic environment can contribute
to premature birth.48,49 Likewise,can Journal of Obstetrics& Gynecology 684.e6
FIGURE 3
Antiangiogenic shift is associated with adverse birth outcomes in women
living with HIV receiving antiretroviral therapy
Individual data points colored by birth outcome. Overlaid regression lines are from linear mixed
effects models, fitted for subject with average values (conditional on fixed effects only).
AGA, appropriate for gestational age; PlGF, placental growth factor; PTB, preterm birth; sEng, soluble endoglin; SGA, small for
gestational age.
Conroy et al. Angiogenic factors across pregnancy in women living with HIV. Am J Obstet Gynecol 2017.
Original Research OBSTETRICS ajog.orgreduced PlGF across gestation was asso-
ciated with SGA, consistent with previ-
ous literature linking PlGF to placental
and fetal growth and development.30,50
Strengths and weaknesses
This study has several strengths
including ultrasound-conﬁrmed gesta-
tional dating and frequent blood sam-
pling. Despite routine clinical
monitoring over pregnancy including
monthly blood pressure and proteinuria
assessments, no women in this cohort
developed preeclampsia. This study is
the ﬁrst to present detailed kinetics data684.e7 American Journal of Obstetrics& Gynecolfrom a low-resource setting where the
burden of disease is greatest, but for
which we have the least amount of data.
The lack of an HIV-uninfected compar-
ison group in this study is a limitation
that prevents us from discussing the
generalizability of the ﬁndings or the
relative impact of maternal HIV infec-
tion. While we did not observe any
changes in angiogenic factor expression
by treatment arm, CD4 count, or HIV-1
RNA viral load at enrollment, additional
studies are needed to delineate the role of
HIV-1 infection on the expression of
angiogenic factors to determine whetherogy DECEMBER 2017infection itself modiﬁes also the risk of
adverse birth outcomes through dysre-
gulated angiogenesis.
Research and clinical implications
This study was conducted in a rural area
of southeastern Uganda where the low
incidence of preeclampsia is consistent
with clinical reports from the region.
While the reason for this is unknown, we
speculate that a relative absence of risk
factors for preeclampsia, including nul-
liparity, coupled with lower weight gain
over gestation contributed to a lower risk
of preeclampsia.59 The median weekly
weight gain in the study was 0.2 kg with
nearly 20% of women gaining no weight
over the study period.60 Additional
studies are needed to validate these
ﬁndings in HIV-infected women and in
populations where preeclampsia is more
common to ascertain the generalizability
of these ﬁndings, and whether early
assessment of angiogenic markers may
have utility in identifying high-risk
pregnancies.
Conclusions
Early changes in angiogenic proteins
may have predictive utility in identifying
women at risk of adverse birth outcomes
in WLHIV receiving ART. While these
ﬁndings need to be prospectively vali-
dated, early identiﬁcation of women at
increased risk of adverse birth outcomes
may facilitate enhanced monitoring and
referral to health care facilities equipped
to manage high-risk pregnancies
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TABLE S1
Descriptive characteristics of the study population by ART treatment arm
Baseline Characteristic
Treatment Arm
P ValueEfavirenz-Based ART, n¼160 Lopinavir/ritonavir -Based ART, n¼166
Age (years) 30 [26, 33] 29.2  5.3 0.623
BMI (kg/m2) 21.2 [19.6, 22.9] 21.6 [20.2, 23.2] 0.074
Socioeconomic status (tertile) 0.611
1 54 (36.2) 57 (35.6)
2 68 (45.6) 67 (41.9)
3 27 (18.1) 36 (22.)
Gestational age enrolment (weeks) 23.6 [19.7, 27.6] 23.5 [19.4, 27.0] 0.711
Previous pregnancies
0 13 (8.3) 7 (4.2) 0.275
1 15 (9.6) 20 (12.1)
2 132 (82.2) 139 (83.6)
Hemoglobin level (g/dL) 11.0 [10.2, 11.8] 11.1 [10.2, 11.7] 0.855
White blood cell count (cells/mm3) 4900 [4100, 6100] 5200 [4300, 6400] 0.134
Platelet count (x109/L) 218.0 [177.5, 255.5] 201.0 [167.0, 239.5] 0.080
CD4+T-cell count (cells/mm3) 373.0 (269.3-497.8) 368.0 (280.5-507.5) 0.575
HIV RNA load (log10copies/mL) 4.286 [3.427, 4.837] 4.097 [3.328, 4.755] 0.468
Outcome Characteristics
Gestational age delivery (weeks) 39 (37-40) 38 (37-39) 0.061
Birth weight (kg) 2910 (2680-3240) 2880 (2650-3210) 0.503
Preterm birth 24 (15.0) 31 (18.7) 0.376
Small-for-gestational age 44 (27.2) 37 (23.9) 0.502
Stillbirth 4 (2.5) 5 (3.0) 1.000
Placental malaria1 14 (10.2) 10 (7.1) 0.363
Continuous variables expressed as median (interquartile range), categorical variables expressed as n (%).
1 Placental malaria defined by a positive finding of a placental blood smear or PCR.
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TABLE S2
Linear mixed effects models of angiogenic markers and preterm birth
Ang-1 Ang-2 sFlt-1 PlGF sEng
Beta SE Beta SE Beta SE Beta SE Beta SE
Fixed Terms
(Intercept) 2.13479 0.4445 2.17519 0.3960 0.43520 0.5145 3.26956 0.6119 2.13733 0.1760
Preterm 0.13387 0.1206 0.15845 0.1068 0.17902 0.1499 0.16196 0.1617 0.16745 0.0475
Gestational age (shifted) 0.00844 0.0064 0.06347 0.0053 0.15426 0.0094 0.36999 0.0260 0.04093 0.0030
Gestational age (shifted) squared 0.01407 0.0010
Maternal age 0.00304 0.0120 0.01471 0.0109 0.00375 0.0132 0.00646 0.0162 0.00102 0.0047
Enrolment BMI 0.00297 0.0161 0.00655 0.0144 0.02036 0.0181 0.00298 0.0216 0.00455 0.0063
Gravidity 0.02431 0.0277 0.01920 0.0253 0.02479 0.0308 0.08150 0.0375 0.01270 0.0109
Gestational age: treatment arm
interaction
0.00132 0.0062 0.00290 0.0063 0.00437 0.0058 0.00402 0.0086 0.00507 0.0025
Number of subjects 320 312 320 320 320
Observations 1104 1049 1104 1104 1085
LR Test against Null Model c2(1) ¼ 1259,
p > 0.05
c2(1) ¼ 2.233,
p > 0.05
c2(1) ¼ 1.444,
p > 0.05
c2(1) ¼ 1.020,
p > 0.05
c2(1) ¼ 12.282,
p < 0.0005*
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TABLE S3
Linear mixed effects models of angiogenic markers and small-for-gestational age
Ang-1 Ang-2 sFlt-1 PlGF sEng
Beta SE Beta SE Beta SE Beta SE Beta SE
Fixed Terms
(Intercept) 2.14191 0.4559 2.13246 0.4024 0.39429 0.5229 3.03817 0.6134 2.12674 0.1820
Stillbirth 0.00712 0.1028 0.13317 0.0920 0.03339 0.1140 0.38094 0.1357 0.00189 0.0408
Gestational age (shifted) 0.00760 0.0064 0.06247 0.0053 0.15138 0.0095 0.36286 0.0264 0.04084 0.0030
Gestational age (shifted)
squared
0.01379 0.0010
Maternal age 0.00374 0.0124 0.01508 0.0111 0.00339 0.0136 0.01062 0.0163 0.00060 0.0049
Enrolment BMI 0.00301 0.0165 0.00489 0.0147 0.01953 0.0185 0.00981 0.0218 0.00400 0.0066
Gravidity 0.01963 0.0287 0.02506 0.0259 0.02451 0.0319 0.06139 0.0379 0.01134 0.0114
Gestational age:
treatment arm
interaction
0.00113 0.0063 0.00296 0.0064 0.00519 0.0059 0.00384 0.0087 0.00445 0.0026
Number of subjects 311 303 311 311 311
Observations 1080 1025 1080 1080 1061
LR Test against
Null Model
c2(1) ¼ 0.0,
p > 0.05
c2(1) ¼ 2.128,
p > 0.05
c2(1) ¼ 0.0878,
p > 0.05
c2(1) ¼ 7.892,
p < 0.005*
c2(1) ¼ 0.0025,
p > 0.05
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TABLE S4
Linear mixed effects models of angiogenic markers and stillbirth
Ang-1 Ang-2 sFlt-1 PlGF sEng
Beta SE Beta SE Beta SE Beta SE Beta SE
Fixed Terms
(Intercept) 2.14007 0.4468 2.20069 0.3979 0.40889 0.5146 3.14340 0.5889 2.12762 0.1788
Stillbirth 0.01616 0.2756 0.24706 0.2320 0.34066 0.3784 1.66380 0.3520 0.26459 0.1110
Gestational age (shifted) 0.00887 0.0064 0.06329 0.0053 0.15278 0.0093 0.36828 0.0259 0.04064 0.0030
Gestational age
(shifted) squared
0.01405 0.0010
Maternal age 0.00309 0.0120 0.01486 0.0109 0.00362 0.0132 0.00881 0.0156 0.00154 0.0048
Enrolment BMI 0.00369 0.0161 0.00480 0.0145 0.01959 0.0181 0.00876 0.0208 0.00297 0.0064
Gravidity 0.02331 0.0278 0.01885 0.0253 0.02359 0.0308 0.07530 0.0359 0.01047 0.0111
Gestational age:
treatment arm
interaction
0.00149 0.0062 0.00316 0.0063 0.00427 0.0058 0.00421 0.0085 0.00471 0.0026
Number of subjects 320 312 320 320 320
Observations 1104 1049 1104 1104 1085
LR Test against
Null Model
c2(1) ¼ 0.0045,
p > 0.05
c2(1) ¼ 1.129,
p > 0.05
c2(1) ¼ 0.819,
p > 0.05
c2(1) ¼ 21.595,
p < 0.0001*
c2(1) ¼ 5.6717,
p < 0.02*
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SUPPLEMENTAL FIGURE 1
Longitudinal changes in angiogenic factors by treatment arm
Scatter plot of plasma levels of angiogenic factors plotted by treatment arm with nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antire-
troviral therapy (ART) in red and protease inhibitor (PI)-based ART in blue. Biomarkers plotted according to gestational age of sample collection:
A, placental growth factor (PlGF); B, soluble fms-like tyrosine kinase (sFlt)-1; C, soluble endoglin (sEng); D, angiopoietin (Ang)-2; and E, Ang-1. Line
indicates best fit line with 95% confidence intervals.
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SUPPLEMENTAL FIGURE 2
Representative plots of soluble endoglin (sEng) levels over gestation in participants destined to have preterm or term
delivery
Trellis plots of 60 randomly selected subjects (n ¼ 30 term, n ¼ 30 preterm). Solid line depicts fitted regression line from linear mixed effect model
(conditional on fixed effects only).
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SUPPLEMENTAL FIGURE 3
Representative plots of soluble endoglin (sEng) levels over gestation in participants destined to have livebirth or
stillbirth infant
Trellis plots of 18 randomly selected subjects (n ¼ 9 livebirth, n ¼ 9 stillbirth). Solid line depicts fitted regression line from linear mixed effect model
(conditional on fixed effects only).
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SUPPLEMENTAL FIGURE 4
Representative plots of placental growth factor (PlGF) levels over gestation in participants destined to have small-for-
gestational-age (SGA) or appropriate-for-gestational-age (AGA) infant
Trellis plots of 60 randomly selected subjects (n ¼ 30 AGA, n ¼ 30 SGA). Solid line depicts fitted regression line from linear mixed effect model
(conditional on fixed effects only).
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SUPPLEMENTAL FIGURE 5
Representative plots of placental growth factor (PlGF) levels over gestation in women destined to have livebirth or
stillbirth infant
Trellis plots of 18 randomly selected subjects (n ¼ 9 livebirth, n ¼ 9 stillbirth). Solid line depicts fitted regression line from linear mixed effect model
(conditional on fixed effects only).
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